Drug · CHEMBL940
GABAPENTIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GABAPENTIN. Drugs and targets, record CHEMBL940. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL940
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- CI-945, DM-1796, GOE 3450, GOE-3450, Gabapentina, Gabapentine, NSC-742194, NSC-759254
- ChEMBL
- Open Targets' highest stage
- Approval, for 6 of its 68 diseases, from DailyMed, PMDA and TTD
- Open Targets
Targets26
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CACNA1A | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/773 |
| CACNA1B | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/774 |
| CACNA1C | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/775 |
| CACNA1D | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/776 |
| CACNA1E | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/777 |
| CACNA1F | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/778 |
| CACNA1G | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/8913 |
| CACNA1H | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/8912 |
| CACNA1I | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/8911 |
| CACNA1S | Voltage-gated calcium channel | Voltage-gated calcium channel modulator | MODULATOR | https://conductscience.org/library/genes/779 |
1 to 10 of 26Source ChEMBL
See all 26 targetsDiseases68
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 68Source Open Targets
See all 68 diseasesTrials425
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03472469 | MAST Trial: Multi-modal Analgesic Strategies in Trauma | Phase 4 | 1,561 | 2021-06-10 | gabapentin | Its name | ClinicalTrials.gov |
| NCT03330119 | Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean Section | Phase 3 | 1,494 | 2021-03-02 | gabapentin | Its name | ClinicalTrials.gov |
| NCT00221338 | Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain | Phase 3 | 750 | 2020-09-10 | gabapentin | Its name | ClinicalTrials.gov |
| NCT01080300 | Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women | Phase 3 | 600 | 2014-03-26 | gabapentin | Its name | ClinicalTrials.gov |
| NCT00777023 | Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women. | Phase 3 | 565 | 2012-02-17 | gabapentin | Its name | ClinicalTrials.gov |
| NCT00755417 | Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women | Phase 3 | 541 | 2012-03-07 | gabapentin | Its name | ClinicalTrials.gov |
| NCT00537940 | Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures | Phase 4 | 482 | 2014-08-08 | gabapentin | Its name | ClinicalTrials.gov |
| NCT00636636 | Safety and Efficacy of Gabapentin in Postherpetic Neuralgia | Phase 3 | 452 | 2012-01-13 | gabapentin | Its name | ClinicalTrials.gov |
| NCT00880191 | Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy | Phase 3 | 430 | 2015-05-21 | gabapentin | Its name | ClinicalTrials.gov |
| NCT01067144 | Stanford Accelerated Recovery Trial (START) | Phase 3 | 422 | 2018-06-28 | gabapentin | Its name | ClinicalTrials.gov |
1 to 10 of 425
See all 425 trialsComparisons in its trials192
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: Number of Participants Discharged From the Hospital With an Opioid Prescription | 527 of 787 | 476 of 774 | 1,561 | NCT03472469 | Trial comparisons |
| Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: deaths from any cause | 29 of 787 | 36 of 774 | 1,561 | NCT03472469 | Trial comparisons |
| Original MMPR - Descending Dose Arm vs MAST MMPR - Escalating Dose Arm: serious adverse events | 29 of 787 | 36 of 774 | 1,561 | NCT03472469 | Trial comparisons |
| Alternate Management vs Control: deaths from any cause | 0 of 475 | 0 of 641 | 1,116 | NCT03330119 | Trial comparisons |
| Alternate Management vs Control: serious adverse events | 0 of 475 | 0 of 641 | 1,116 | NCT03330119 | Trial comparisons |
| Presence of Non-Drug Therapy vs Absence of Non-Drug Therapy: Number of Participants Who Responded to Treatment With Gabapentin by Presence or Absence of Non-Drug Therapy | 34 of 45 | 605 of 1,000 | 1,045 | NCT00567268 | Trial comparisons |
| Age <65 Years vs Age >=65 Years: Number of Participants Who Responded to Treatment With Gabapentin by Age (<65 Versus >=65 Years) | 545 of 933 | 94 of 112 | 1,045 | NCT00567268 | Trial comparisons |
| Gabapentin vs Placebo: Incidence of Postoperative Delirium by Study Group | 84 of 350 | 72 of 347 | 697 | NCT00221338 | Trial comparisons |
| Gabapentin vs Placebo: deaths from any cause | 0 of 350 | 1 of 347 | 697 | NCT00221338 | Trial comparisons |
| Gabapentin vs Placebo: serious adverse events | 31 of 350 | 44 of 347 | 697 | NCT00221338 | Trial comparisons |
1 to 10 of 192
See all 192 comparisons in its trialsPapers from its trials165
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials12
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Selective Reminding Task | 4 | 0 | ConductCognition |
| Symbol Coding | 4 | 0 | ConductCognition |
| Verbal Fluency | 2 | 1 | ConductCognition |
| Category Fluency | 1 | 1 | ConductCognition |
| Digit Span Test | 1 | 1 | ConductCognition |
| Hidden Path Learning | 1 | 0 | ConductCognition |
| Iowa Gambling Lite | 1 | 0 | ConductCognition |
| Psychomotor Vigilance Task | 1 | 1 | ConductCognition |
| Simple Reaction Time | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
1 to 10 of 12
See all 12 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL940
GET https://conductscience.org/api/drugs/v1/CHEMBL940/targets?page=2